Exact Mass: 481.1301214

Exact Mass Matches: 481.1301214

Found 228 metabolites which its exact mass value is equals to given mass value 481.1301214, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Yersiniabactin

C21H27N3O4S3 (481.1163622000001)

A member of the class of thiazolidines that is (4S)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid which is substituted at position 2 by a (1S)-1-hydroxy-1-{(4R)-2-[(4R)-2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl}-2-methylpropan-2-yl group. A siderophore found in the gram-negative bacterium species, Yersinia enterocolitica and Yersinia pestis. D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents

Talampicillin

4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylicacid, 6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-,1,3-dihydro-3-oxo-1-isobenzofuranyl ester, (2S,5R,6R)-

C24H23N3O6S (481.13074980000005)

J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D08557

Cycloprothrin

C26H21Cl2NO4 (481.08475660000005)

Pranlukast

C27H23N5O4 (481.17499580000003)

R - Respiratory system > R03 - Drugs for obstructive airway diseases > R03D - Other systemic drugs for obstructive airway diseases > R03DC - Leukotriene receptor antagonists D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D020024 - Leukotriene Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent

Rosuvastatin

(3R,5S,6E)-7-(4-(4-Fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulphonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid

C22H28FN3O6S (481.16827600000005)

Rosuvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reducuase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Rosuvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

Pranlukast

N-[4-oxo-2-(2H-1,2,3,4-tetrazol-5-yl)-4H-chromen-7-yl]-4-(4-phenylbutoxy)benzamide

C27H23N5O4 (481.17499580000003)

Pranlukast is only found in individuals that have used or taken this drug. It is a cysteinyl leukotriene receptor-1 antagonist. It antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.Pranlukast selectively antagonizes leukotriene D₄ (LTD₄) at the cysteinyl leukotriene receptor, CysLT₁, in the human airway. Pranlukast inhibits the actions of LTD₄ at the CysLT₁ receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.

(3R,5R)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

(3R,5R)-7-[4-(4-Fluorophenyl)-2-(N-methylmethanesulphonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

C22H28FN3O6S (481.16827600000005)

Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)-, (2S)-

Pentanamide, N-(cyanomethyl)-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4-(methylsulfonyl)(1,1-biphenyl)-4-yl)ethyl)amino)-, (2S)-

C23H26F3N3O3S (481.1646882000001)

Talampicillin

2-Amino-N-(3,3-dimethyl-7-oxo-2-{[(3-oxo-1,3-dihydro-2-benzofuran-1-yl)oxy]carbonyl}-4-thia-1-azabicyclo[3.2.0]heptan-6-yl)-2-phenylethanimidate

C24H23N3O6S (481.13074980000005)

Yersiniabactin

2-(1-hydroxy-1-{2-[2-(2-hydroxyphenyl)-4,5-dihydro-1,3-thiazol-4-yl]-1,3-thiazolidin-4-yl}-2-methylpropan-2-yl)-4-methyl-4,5-dihydro-1,3-thiazole-4-carboxylic acid

C21H27N3O4S3 (481.1163622000001)

6-Hydroxydelphinidin 3-glucoside

2- (3,4,5-Trihydroxyphenyl) -3- (beta-D-glucopyranosyloxy) -5,6,7-trihydroxy-1-benzopyrylium

C21H21O13 (481.0982116)

Maybridge4_000191

C22H28ClN3O3S2 (481.1260528000001)

Oprea1_736509

C29H24ClN3O2 (481.1556954)

2,3-di(acetyloxy)-4-anilino-1-[1,2-di(acetyloxy)ethyl]-4-oxobutyl acetate

C22H27NO11 (481.15840320000007)

(1E)-5-methoxy-6-hydroxycinnamenyl-(1->6)-5,6-dihydrosanguinarine|maclekarpine E

C29H23NO6 (481.1525298)

C28H23N3O5

C28H23N3O5 (481.16376280000003)

(4Z)-5-{6-O-[(2E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoyl]-beta-glucopyranosylsulfanyl}pent-4-enenitrile

C22H27NO9S (481.1406452000001)

notoamide N

C26H28ClN3O4 (481.1768238000001)

Rosuvastatin

(3R,5S,6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid

C22H28FN3O6S (481.16827600000005)

C - Cardiovascular system > C10 - Lipid modifying agents > C10A - Lipid modifying agents, plain > C10AA - Hmg coa reductase inhibitors D057847 - Lipid Regulating Agents > D000960 - Hypolipidemic Agents > D000924 - Anticholesteremic Agents D004791 - Enzyme Inhibitors > D019161 - Hydroxymethylglutaryl-CoA Reductase Inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C1655 - HMG-CoA Reductase Inhibitor D009676 - Noxae > D000963 - Antimetabolites Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 2802

N2-(Pyrene-1-yl)methyl-deoxyguanosine

C27H23N5O4 (481.17499580000003)

Ala Cys Cys Trp

(2S)-2-[(2R)-2-[(2R)-2-[(2S)-2-aminopropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C20H27N5O5S2 (481.14535320000005)

Ala Cys Trp Cys

(2R)-2-[(2S)-2-[(2R)-2-[(2S)-2-aminopropanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid

C20H27N5O5S2 (481.14535320000005)

Ala Trp Cys Cys

(2R)-2-[(2R)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C20H27N5O5S2 (481.14535320000005)

Cys Ala Cys Trp

(2S)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]propanamido]-3-sulfanylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C20H27N5O5S2 (481.14535320000005)

Cys Ala Trp Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]propanamido]-3-(1H-indol-3-yl)propanamido]-3-sulfanylpropanoic acid

C20H27N5O5S2 (481.14535320000005)

Cys Cys Ala Trp

(2S)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]propanamido]-3-(1H-indol-3-yl)propanoic acid

C20H27N5O5S2 (481.14535320000005)

Cys Cys Glu Lys

(2S)-6-amino-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-4-carboxybutanamido]hexanoic acid